Guardant Health (NASDAQ:GH) Director Alex Azar II Sells 826 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Alex Azar II sold 826 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total transaction of $144,550.00. Following the completion of the transaction, the director owned 825 shares in the company, valued at approximately $144,375. This trade represents a 50.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Trading Up 4.7%

NASDAQ GH traded up $8.20 on Thursday, hitting $183.10. 1,858,277 shares of the company’s stock traded hands, compared to its average volume of 2,252,181. Guardant Health, Inc. has a 1-year low of $55.38 and a 1-year high of $183.51. The firm’s 50-day moving average price is $160.33 and its two-hundred day moving average price is $126.47. The firm has a market capitalization of $24.57 billion, a PE ratio of -52.46 and a beta of 1.57.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. During the same quarter in the previous year, the company earned ($0.44) EPS. The firm’s revenue was up 44.3% compared to the same quarter last year. On average, research analysts anticipate that Guardant Health, Inc. will post -2.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on GH shares. Guggenheim lifted their price objective on Guardant Health from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Stephens raised their target price on Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Piper Sandler reaffirmed an “overweight” rating on shares of Guardant Health in a research note on Tuesday. BTIG Research restated a “buy” rating and issued a $195.00 price target on shares of Guardant Health in a research note on Wednesday, September 2nd. Finally, Canaccord Genuity Group upped their price objective on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $188.12.

Institutional Investors Weigh In On Guardant Health

Hedge funds have recently modified their holdings of the company. Orbimed Advisors LLC purchased a new position in Guardant Health during the first quarter worth about $40,199,000. GSA Capital Partners LLP purchased a new stake in shares of Guardant Health in the 2nd quarter valued at approximately $1,772,000. Ninepoint Partners LP acquired a new stake in shares of Guardant Health during the 2nd quarter worth approximately $2,853,000. SWS Partners acquired a new stake in shares of Guardant Health during the 2nd quarter worth approximately $11,190,000. Finally, Eagle Health Investments LP purchased a new stake in shares of Guardant Health during the 2nd quarter valued at approximately $45,112,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.